Trials / Terminated
TerminatedNCT00899353
Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM)
Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Marshall University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS), or Smoldering Multiple Myeloma (SMM), whose disease does not currently require treatment. The primary aim of the study is to determine if the Omega 3 supplementation will help prevent or delay progression of the disease to a stage that requires treatment.
Conditions
- Monoclonal Gammopathy of Undetermined Significance
- Smoldering Multiple Myeloma
- Chronic Lymphocytic Leukemia
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Omega 3 Fatty Acid | Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months. |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2011-12-01
- Completion
- 2012-10-01
- First posted
- 2009-05-12
- Last updated
- 2013-12-12
- Results posted
- 2013-11-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00899353. Inclusion in this directory is not an endorsement.